Events /// Investor News /// Investment Case /// Resources
Bayer is committed to providing sustainable solutions that address humanity’s most fundamental needs for essential healthcare and nutritious food. The Bayer Investor Relations Team is dedicated to creating transparency, fostering dialogue, and delivering value to our stakeholders.
Upcoming Events and Highlights
Investor News
Share Price / Index
May 28, 2025
Not intended for U.S. and UK Media
Sevabertinib (BAY 2927088) granted FDA Priority Review for the treatment of patients with HER2-mutant non-small cell lung cancer
May 23, 2025
Not intended for U.S. and UK Media
Eylea™ 8 mg with extended 6-month treatment interval recommended for approval in EU
May 22, 2025
Not intended for U.S. and UK Media
Eylea™ 8 mg approved in China for wet age-related macular degeneration
Discover More
